How can teams compare competing drug programs at the molecule level? This RAS-inhibitor case study shows how AI-powered LCA and SAR turn patents into prioritized leads, structural insight and traceable competitive intelligence.
Browsing: Structure-Activity Relationship
Patent SAR Analysish-cGASFLInhibition rateHot R&D Patent cGAS Inhibitor SAR: Structural Changes Behind Activity First, this…
Patent SAR AnalysisToxicityMTDHot R&D Patent Dual VDR-HDAC Compounds: Potency, Toxicity, and Activity Cliffs First, this…
Patent SAR AnalysisUse of Anti-Nectin-4 Antibody-Drug Conjugate for Treating TumorActivityHot R&D Patent Anti-Nectin-4 ADCs for…
Patent SAR AnalysisBacterial reverse mutationmean # pos. WellsHot R&D Patent High-Purity Vorinostat: Mutagenicity Data in…
Patent SAR AnalysisMyt1 kinaseClearance of Human microsomeHot R&D Patent PKMYT1 Inhibitor SAR: 177 Compounds and…
Patent SAR AnalysisRAW264.7 macrophagesCell ViabilityHot R&D Patent Inflammatory Macrophage Activity: A Three-Compound Patent Dataset First,…
Patent SAR AnalysisHuman soluble CD73%ID/mLHot R&D Patent CD73 Diagnostic Compounds: What the Patent Activity Data…
Patent SAR AnalysisHIV-1 pseudovirusAUC0-infHot R&D Patent Polycyclic Carbamoyl Pyridones Against HIV-1: A 74-Record Patent SAR…